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This review aims to summarise our knowledge to date on the protein complement of the synovial
fluid (SF). The tissues, structure and pathophysiology of the synovial joint are briefly described.
The salient features of the SF proteome, how it is composed and the influence of arthritic disease
are highlighted and discussed. The concentrations of proteins that have been detected and
quantified in SF are drawn together from the literature on osteoarthritis, rheumatoid arthritis
and juvenile idiopathic arthritis. The measurements are plotted to give a perspective on the dy-
namic range of protein levels within the SF. Approaches to proteomic analysis of SF to date are
discussed along with their findings. From the recent literature reviewed within, it is becoming
increasingly clear that analysis of the SF proteome as a whole, could deliver the most valuable
differential diagnostic fingerprints of a number of arthritic disorders. Further development of
proteomic platforms could characterise prognostic profiles to improve the clinician’s ability to
resolve unremitting disease by existing and novel therapeutics.
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1 The synovial joint triad: SF, synovial
membrane, articular cartilage
In order to study the joint disease we need to realise the
importance of the interplay between three components:
Synovial fluid (SF), synovial membrane (SM) and articular
cartilage (see Fig. 1A). In what follows, we use the term
‘synovial fluid’ to describe the protein components that are
soluble in the synovial joint. A number of body fluids are
derived from or ‘dialysates’ of plasma, and thus share some
of its protein content. SF, cerebrospinal fluid and urine fea-
ture within this group. SF contains a number of specific
additions made from proximal joint tissue, including SM or
articular cartilage. SFnot only lubricates the bearing surfaces
of the joints, but also permits the transport of nutrients from
SM to joint cartilage and waste products to the lymph.
The SM, in healthy conditions, is comprised of a layer of
cells one to three cells deep (see Fig. 1B). These cells, which
are in direct contact with the joint cavity, are mainly macro-
phage and fibroblast like [1, 2]. The cells are imbedded in a
collagen and hyaluronan-rich matrix [3]. The SM is unique
compared to the linings of other body cavities as it lacks a
true basement membrane; however, this intimal matrix acts
as a semipermeable membrane. Furthermore, the superficial
capillary network is also fenestrated which may be important
in the egression of vascular components beyond the intimal
tissue and into the SF [4]. The surface of diarthrodial joints is
covered by articular cartilage which is essentially avascular.
Hyaline (articular) cartilage is composed of a small number
of chondrocytes, which produce, and are imbedded in an
extracellular matrix of collagen fibrils and proteoglycans.
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Figure 1. Diagram to represent the structure and pathology of the synovial joint. A comparison is made between the normal and arthritic
joint to highlight the main points of protein entry into the SF in disease (A). The arthritic synovial joint is characterised by inflammation and
thickening of the SM and a consequent influx of lymphocytes and macrophages through a revascularised SM. In established disease, the
proinflammatory environment of SF can stimulate degradation of the articular cartilage, through activated cells. A schematic representa-
tion of normal SM in health and the changes that occur in the membrane during inflammation and the subsequent changes observed in the
SF are noted (B).
2 Sources of SF components
Normally plasma proteins can enter the SF by passive diffu-
sion. Ropes and Bauer [5, 6] in their classic studies of syno-
vial effusions, equated SF to a dialysate of blood plasma.
They found a wide assortment of electrolytes and small
molecules present in the effusions at concentrations similar
to those of plasma. Concentrations of larger proteins remain
substantially less in SF than in plasma (see Table 1). In aspi-
rates from normal knees, the total protein is only 19 mg/mL,
a value less than 30% of that in normal plasma [7]. The
intrasynovial concentration of any protein represents the net
contributions of plasma concentration, synovial blood flow,
microvascular permeability and lymphatic removal. How-
ever, a number of other properties predict whether a mole-
cule can enter the joint fluid, including; molecular weight,
charge, solubility and protein binding [8].
Hyaluronan (HA), a high molecular weight glycosami-
noglycan, is secreted into the dialysate from B-type synovium
cells. HA is the major macromolecular constituent of SF and
it forms a complex with the protein fraction of the dialysate.
HA performs a protective role in the SF of articulating joints,
the vitreous humour of the eye and in most connective tis-
sues [9].
Until relatively recently it was believed that almost all
constituents of SF were obtained solely from plasma. How-
ever, with the development of sensitive techniques, it is evi-
dent that many of the constituents of SF present in disease
states are produced locally. These include: cytokines [10],
proteases [11] and antibodies such as rheumatoid factor [12].
These molecules are produced by a variety of cells within the
SM including Type A synoviocytes, fibroblasts and infiltrat-
ing inflammatory cells. In healthy conditions, the cellular
component of SF is low, with the occasional secretion from
synoviocyte, chondrocyte, neutrophil and lymphocyte. In
chronic conditions such as osteoarthritis (OA), or chronic
inflammatory diseases such as rheumatoid arthritis (RA)
and juvenile idiopathic arthritis the primary infiltrates are
lymphocytes and plasma cells [13]. The homogeneity of the
SM infiltrate in an individual patient enables the use of
synovial biopsies to evaluate disease severity and response to
treatment [14]. The predominant T cell subtype infiltrate in
most chronic arthritides are T helper (CD41) cells [15], al-
though in the spondyloarthropathies CD81, suppressor/
cytotoxics cell appear to predominate [16].
3 SF proteins quantified by conventional
nonglobal proteomic analyses
The following section summarises our knowledge, from the
literature to date, of proteins identified within SF by conven-
tional, nonglobal proteomic methods. These methods are
limited, by definition, in their ability to study more than one
or two proteins at a time within an experiment. In other
words they do not possess multiplex or high throughput
capabilities characteristic of modern proteomic techniques.
Typical examples of antibody-based methods used to study
SF include ELISA, Western blotting and immunoprecipita-
tion. Although each of these methods has its limitations for
studying SF in a complex multifactorial disease such as
arthritis, they have provided invaluable information on indi-
vidual mechanisms involved in joint development and dis-
ease. Indeed, as medical research shifts focus towards the
principles of integrated systems biology, the more traditional
methods will remain important in validation and can be used
in a complementary fashion to further explore large prote-
omic data sets.
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Table 1. Concentrations of the most abundant proteins in SF and blood
Molecular
weight (kDa)
SF Serum/plasma
Normal OA RA Normal OA RA
Hyaluronan 26106 3.2 1.5 0.17–2.0 – – –
Fibrinogen 340 – 0.15–2.10 0.25–0.55 3.0 – 7.0
Albumin 69 12.0–20.0 11.0–34.0 8.0–35.0 32.7 26.0 29.2–44.0
Haptoglobin 100 0.1 0.2 0.9–4.0 1.8 2.0 2.4–6.0
Ig G 156 – 4.0–30.0 10.3–11.0 – 4.0–12.0 11.0–20.1
TOTAL PROTEIN – 19.0 40.0–68.0 38.0–84.0 67.7 – 70.0
Concentrations are in units of ng/mL; the approximate molecular weights of each protein are also shown. The data compiled from the lit-
erature [4, 40, 93–95] are also plotted alongside the concentration intervals for less abundant proteins in the arthritic SF in Fig. 2.
In the interests of highlighting only those proteins with
relevance to clinical outcome, a list was compiled from stud-
ies with expression levels correlated to defined pathological
processes. Proteins are categorised by their involvement
invarious established aspects of joint pathology. These cate-
gories include inflammation, degradation, cell migration/
proliferation, angiogenesis and immunobiology (see Fig. 2).
Priority, when compiling the data, was thus given to litera-
ture which gave detailed concentrations of proteins in units
of mass per unit volume and these were standardised to
nanogram per millilitre for comparative purposes. This
approach permits a more authoritative view of the dynamic
range of protein levels in the SF. It is important to note that
data pertaining to how serum or plasma levels relate to those
in the SF were not always present. These data are essential if
we are to rely on biological assay of indicators of joint disease
in blood in order to make clinically relevant decisions.
Though blood is more easily accessed, it would be careless to
preclude simultaneous analysis of both fluids at the current
juncture in biomarker discovery as it is crucial to have proof
of correlation between the two fluids.
It is important to appreciate the stages in the pathology of
arthritis which explain in part why these classes of proteins
are found at concentrations beyond the normal ranges for SF
and even match plasma/serum. The onset of an arthritic dis-
order is heralded by two fundamental signs of inflammation.
In the first of these, SMwhich encapsulates andnourishes the
joint, becomes swollen and thickens (synovitis) due to lym-
phocytes becoming bound to (lymphostasis) and migrating
beyond the synovial blood vessels (Fig. 1B). Hyperplasia, or
thickening of the membrane, is promoted by cytokine and
growth factor release from migrating cells. During the second
component of inflammation, the SMbecomes revascularised,
making it redder than normal [17–21]. This angiogenic pro-
cess is initiated by a higher oxygen demand from increases in
cell numbers within the SM and hypoxia imposed by lym-
phocyte engorged arterioles. The revascularisation is altered,
however, by the proinflammatory cytokine-enriched environs
(IL-1a, IL-6, tumour necrosis factor alpha (TNFa)) and results
in aberrant growth of tortuous, permeable vessels which
propagate beyond the confines of the synovium.This ‘pannus’
impinges on the cartilage and can result in irreparable degra-
dation of the articular surfaces. In describing the early stages
of arthritic pathology, points of entry for proteinsnot normally
present in the SF should have become apparent: abnormal
blood vessels, the swollen SM and leukocyte cells which
penetrate within it.
The main factors limiting protein entry into the SF from
capillaries are the number and size of fenestrations. Increased
blood flow and vessel permeability means that proteins which
are normally excluded enter now, such that virtually all
plasma proteins will reach equivalent concentrations within
the joint. Molecular size no longer acts as a limiting factor in
what can enter or leave the inflamed joint. This change in fil-
tration is evident from the increased concentrations of higher
molecular weight proteins by comparison to the normal joint,
such as haptoglobin (85 kDa), Ig G (150 kDa) and fibrinogen
(340 kDa, in complex). See Table 1 for the expected ranges of
each of the most abundant proteins in both SF and plasma
from normal and arthritic patients. In general smaller protein
molecules such as albumin are present in normal joints at
greater concentrations than larger molecules such as the Igs.
The concentrations of cytokines such as IL-1, IL-6 and TNFa
albeit on the picogram scale often outstrip plasma levels [22–
26]. This clearly indicates the expression localised within or
proximal to the joint fluid and thus it is likely that such indi-
cators will be detected in SF at an earlier stage of the disease,
than in plasma. Many associated regulatory molecules have
also been detected including receptor agonists and soluble
receptors shed from leukocytes, macrophages and other
invaded peripheral blood cells.
As may be expected, the concentration of a great number
of proinflammatory cytokines and acute phase markers
derived from synovium and migrating leukocytes increase in
SF, in line with the degree of inflammation [24, 25, 27, 28].
Those included within this review include interleukin-1b,
interleukin-6, C reactive protein, serum amyloid A and the
recently discovered group of S100 proteins [29, 30]. It is
timely to remind at this point that we are only glimpsing a
‘snapshot’ in the timeline of the disease process, which is in
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Figure 2. The concentration intervals of synovial proteins in the arthritic joint. Concentrations of several functional classes were compiled
from the literature. The data were normalised to nanogram per millilitre to allow the comparison across a log scale of protein concentra-
tion. The dynamic range extends from mg/mL concentrations for abundant proteins such as albumin and IgG, to pg/mL for scarce proteins,
i.e. proinflammatory protein TNFa.
constant flux. Therefore samples obtained in a serial fashion,
from diagnosis, through early to established disease are
invaluable if we wish to detect putative prognostic bio-
markers.
As the rate of joint destruction increases proteolytic
enzymes (matrix metalloproteinase; MMPs) [26, 31–33] and
the peptide products of their degradation, cartilage frag-
ments [26, 34–36], become apparent within the SF. Cyto-
kines such as TNFa and interleukins are released within the
synovial blood vessels which induce the expression of inter-
cellular adhesion molecules such as ICAM and E-cadherin.
These extracellular proteins are thought to promote the
accumulation of activated T cells and soluble forms have
been detected in SF [37].
3.1 Limitations of methods of analysis used to date
It is clear from the previous section that many factors are
involved in the initiation and the perpetuation of joint
inflammation as well as joint destruction and repair. The
analysis of single or even groups of mediators is thus un-
likely to be as informative as the analysis of a large number of
proteins and peptides. Thus to understand what causes joint
damage in arthritis we need to look at all the mediators of
inflammation, anti-inflammation, destruction and repair.
In the last few decades, theories on the predictors and
mechanisms of disease have followed a common trend,
whether it be T cells, cytokines, fibroblasts, proteases or
osteoclasts. What is clear, however, is that no single agent or
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process is wholly responsible rather there is an interaction of
these processes leading to a protein footprint that char-
acterises a particular inflammatory insult to the joint. For
that reason proteomics is an ideal platform to examine the
processes active in arthritis. For a proteomic approach, how-
ever, to be successful two conditions are essential:
(i) Expertise in the handling, processing and proteomic
analysis of samples.
(ii) Expertise in the classification, and clinical examina-
tion of patients to be studied.
4 Considerations and technical challenges
of SF proteomics
4.1 Sample characteristics and processing
Paracelsus (1493–1541) introduced the term ‘synovia’ to
name the intra-articular fluid, due to its egg-like appearance
and consistency [38]. SF is normally clear, pale and straw
coloured in the healthy joint and has a characteristic viscosity
attributable to the HA component. SF is only present in
small amounts within the normal knee joint (a few drops to a
maximum of 4 mL) [39]. The volume of this fluid increases
when disease is present to provide an effusion that is clini-
cally apparent and may be easily aspirated for study, hence
most knowledge of human SF comes from patients with
joint disease. Because of the clinical frequency, volume, and
accessibility of knee effusions, our knowledge is largely lim-
ited to findings in that joint. Osteoarthritic SF retains the
normal colour, clarity and high viscosity but is increased in
amount. SF from RA is increased in amount, can be cloudy
from suspended cells, less viscous and may clot on standing
due to a higher fibrinogen content [40]. The mean molecular
weight distribution of HA in RA SF is moderately lower than
that of normal fluid [9]. The total amounts of HA actually
increase, so pathological fluids are characterised by the dilu-
tion of HA and not by the lack of high molecular weight
forms. In the context of the physical attributes of SF, this
translates into a fluid viscosity which is easier to pipette or
aliquot than normal joint fluid. In view of the high viscosity
of SF samples, hyaluronidase treatment can be used to facil-
itate LC techniques such as size fractionation or affinity
depletion [41].
Normal SF does not clot as it does not contain sufficient
fibrinogen, though inflammation increases the ingress of
larger clotting components from the peripheral blood supply.
Therefore pathological fluids can clot, such that the speed
and size of clot formation relate to the severity of joint
inflammation. The recovery of SF does not normally require
anticoagulants, though samples can be collected in K-EDTA
blood tubes for convenience [42]. Clots can form if samples
are left for over 1 h at room temperature, prior to cen-
trifugation, though this will compromise the stability of the
SF proteome. Storage and handling of SF should follow
similar guidelines agreed by the Plasma Proteome Initiative
at the most recent HUPO congress. Briefly, cellular material
should be removed from samples by centrifugation, aliquots
made and stored at 2807C. Protease inhibitors can be added
to the sample to protect against degradation during purifica-
tion, prefractionation or IPG strip rehydration for 2-DE [42,
43]. It should be noted, however, that some of the peptide
components such as leupeptin in inhibitor cocktails can
complicate mass spectrometric identifications.
If a fluid is opaque, yellow-white and of reduced viscosity
(low HA concentration), a high total leukocyte count with
polymorphonuclear (PMN) cell dominance is the most likely
cause. In general, small lymphocytes, monocytes and ma-
crophages (or synovial lining cells) make up the remainder
of the leukocytes, and some of each can be found in most of
the joint fluids. Normal human SF contains few leukocytes,
and PMN cells are difficult or even impossible to find [39].
The total cell count can be used to gauge the activity of the
inflammatory disease within the joint. The normal SF has on
average a count of 150 cells/mL, whereas OA and RA have
average counts of 400 and 10 000, respectively. In the case of
OA, clarity may decrease due to the presence of cartilage
fragments as the condition progresses.
The SFproteome, as a partial eluent of plasma, is likely to
have similar physical attributes which determine the efficacy
of a particular analytical approach. SF is slightly alkaline with
a pH of approximately 7.3–7.4, which falls during muscular
activity. The normal total protein content of SF is approxi-
mately 19 mg/mL [7]; normal plasma is 67.7 mg/mL; in
arthritic disease the synovial proteome can equate from 38.0
to 84.0 mg/mL [40]. See Table 1 for concentrations of the
most prevalent proteins in both fluid types. A number of
proteins including albumin, Ig, haptoglobin, fibrinogen and
the glycoprotein HA have been detected at high milligram
per millilitre concentrations within SF. Albumin is the most
abundant protein in SF, accounting for ,64% of total pro-
tein in normal SF. Immunglobulin levels are normally low
in SF, but levels in RA patients become equivalent to those of
serum on average 9.5 mg/mL (see Table 1).
The dynamic range between potentially clinically useful
proteins can differ by a factor of 1010. For example, TNFa and
haptoglobin have been detected at picogram and milligram
per millilitre quantities, respectively, close to the detection
limits of existing antibody-based affinity methods (see Fig. 2).
Further heterogeneity is introduced to various plasma and
SF proteins by glycosylation, evident for example among
haptoglobins and Igs (see Fig. 3).
To reduce the dynamic range of the SF and enrich lower
ab undance proteins, serum albumin and Igs can be
removed by affinity depletion columns [41]. Although high
concentrations of IgGs and albumin may physically mask
less abundant proteins with similar pI and molecular
weight coordinates in 2-DE, depletion columns may also
bind proteins in a nonspecific manner [44]. Whether bound
directly to a column or indirectly through secondary bind-
ing to Igs, and particularly to albumin, depletion should
only be used when whole sample integrity is not required.
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Figure 3. Fluorescence differential in gel electrophoresis (DIGE) of SF and plasma from juvenile idiopathic arthritis (JIA) patients. Briefly,
ten paired SF and plasma samples were individually labelled with Cy 5 and Cy 3 flurophores. An internal standard of all 20 samples was
pooled and labelled with Cy 2. 50 ug of each sample pair and internal standard were combined and loaded onto pH 4–7 IPG strips. After IEF
in the first dimension, proteins were separated in the second dimension by 12% PAGE. Gels were imaged on a laser scanner with spot
matching, normalisation and quantification were processed by a dedicated software package. Nine synovial ‘specific’ (A) and plasma
specific (B) proteins are circled and numbered. A number of distinctive protein spot trains are highlighted (boxes), including albumin, Igs
and haptoglobin. Identities were made by inference to data published in Expasy 2-DE protein maps and literature (http://expasy.org/ch2d/)
[42, 92]. The normalised intensity of each protein across 10 JIA patients is plotted as a bar chart (C) such that black and white bars represent
the mean normalised protein spot intensities for SF and plasma, respectively (error bars represent SD).
‘Albuminomics’ itself is a burgeoning offshoot of this very
depletion strategy, where research can be conducted on
retained depletion columns to investigate the variety of pep-
tides that are bound to this carrier molecule [45]. The wide
dynamic range of the synovial proteome precludes the anal-
ysis of low abundance, lower molecular weight protein or
peptide species by MS unless the sample is prefractionated.
Intact and partially degraded proteins or peptide fragments
are more likely to leach into the circulating plasma [46]. Low
molecular weight components can be enriched by size
exclusion or RP chromatography [41, 47]. Characteristics of
published and several new proteomic technologies applica-
ble to arthritis research are reviewed in the literature [48–50].
5 Approaches and findings from global
proteomic analyses
5.1 SF analysis
A number of the recent technological advances in high
throughput protein separation and identification have
already been applied to the analysis of the synovial proteome.
This section tracks the progress made to date, starting with
classic 2-DE. Early on in the history of body fluid proteomics,
Felgenhauer and Hagedorn suggested the 2-DE technique to
screen complex soluble protein mixtures for pathological
components. Despite the technological restrictions of the
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time, they were able to identify the SF as a filtrate of serum
due to the resemblance of separated protein patterns be-
tween the two body fluids [51]. The authors propose that the
serum-derived fraction of a body fluid, such as SF, depends
on the selectivity of the respective blood–body fluid barrier.
The qualitative feature of the protein ‘maps’ derived by 2-DE
remains one of its unique strengths, allowing the identifica-
tion of unique or differentially expressed proteins and their
PTMs. Scott et al. some years later detected a high molecular
weight fibrin-complex species in RA SF by 2-DE immuno-
blots. The fibronectin complexes were able to remove Ig
complexes from SF in vitro and thought to assist in phagocy-
tosis [52]. Further study by 2-DE revealed that a number of
fibronectin complexes were present in SF, whereas only a
single fibronectin component was present in paired serum
from RA patients [53]. SF from osteoarthritic patients, ana-
lysed in a later series of 2-DE immunblot-based investiga-
tions, was found to contain EIIIA sequences which can pro-
mote catabolic responses in chondrocytes [54, 55].
The reproducibility of 2-DE as an analysis technique was
first tested extensively on SF and paired serum and synovial
tissue by Fritz et al. [56], with repeat runs giving consistent
protein spot patterns. They found though, that the number
of proteins in SF (45) was always lower than in matched
serum (50) or tissue (69). Spot numbers were so low due to
the poor resolution and dynamic range attributes of the cus-
tom micro 2-DE system employed, but the group were the
first to successfully separate soluble protein from the syno-
vial tissue and developed their ideas further to try and char-
acterise the histology of cryostat sections [57]. The only dif-
ference in spot pattern noted between RA and non-RA
patients was the increased density of the IgG spots [56]. In
spite of limited sensitivity, these investigations demonstrated
that an additional validity and clarity could be added by the
introduction of adjacent tissues such as SM, cartilage and
bone, such that the origin of protein expression can be
established. The ability to localise protein expression could
help in the development of more effective therapeutics, di-
rected to specific areas of the joint depending on the indi-
vidual patient’s state of disease. Sera and SF from RA
patients have also been evaluated for anti-HLA class II beta-
chain antibodies using single and 2-D immunoblots [58].
The antibodies from RA sera and SFs which reacted with
class II beta-chain determinants were predominantly IgM
and IgA with minimal IgG. Thus determinants of auto-
immunity, a characteristic of established arthritic disease,
can also be investigated in the SF of inflamed joints.
Since these preliminary proteomic studies, vast
improvements have been made in the various components
required for sensitive and high resolution 2-DE. Advances
include the manufacture of IPGs for more precise IEF, a new
generation of fluorescent stains and software-based spot
recognition and analysis, all of which have increased the
sensitivity and reliability of the 2-DE technique. The advent
of soft ionisation of peptides from protein digests also justi-
fied the application of MS to identify spots cut from gels.
Sinz et al. [42] used an adaptation of this ionisation known as
MALDI PMF in conjunction with high capacity 2-DE, where
up to 900 mg of the SF protein was loaded per IPG strip.
Paired SF and plasma samples were separated over a pH 4–7
range, with approximately 300 spots per gel visualised by
coomassie staining. Among the 150 proteins identified, a
number of differentially expressed proteins were detected in
the plasma and SF of RA patients, but not in OA patients.
Calgranulin B, or migration inhibitory factor-related protein-
14 (MRP14), was identified exclusively in five out of six SF
samples from RA [42]. This molecule could act as a marker of
activated phagocytes recruited to the inflamed joint as these
initial findings have been validated through a number of
other studies [41, 59]. Interestingly, calgranulin A (MRP8),
which forms complexes with and is coexpressed with
MRP14, could not be identified in any of the gels. Cal-
granulin C (MRP12) detected using gels with a higher re-
solving power may contribute to leukocyte migration into the
chronically inflamed joint and has been detected in SF by
other groups [60]. Plasmin derived, fibrinogen beta chain
degradation products detected in the joint are thought to
result from an imbalance between fibrin formation and deg-
radation and are indicative of a proteolytic environment.
Serum amyloid A, which may have detrimental effects in
chronic inflammation evident in established rheumatic dis-
ease, was found in the low molecular mass region of gels in
agreement with Doherty et al. [61]. The calcium binding
protein MRP14 (S100A9) was further characterised in SFas a
disease-associated discriminatory marker by Drynda et al.
[59]. Results were confirmed by ELISA measurements of the
MRP8/14 complex and demonstrated that plasma levels cor-
relate well with those in SF. Therefore, a blood test may be
able to distinguish RA patients from a range of other
inflammatory disorders including OA. Furthermore, hetero-
complex levels are reduced in response to anti-TNFa treat-
ment, showing promise as a molecular monitor on ther-
apeutic status [59].
Evidence concerning the reliability of modern 2-D gel
techniques to analyse SF has been recently published, which
should encourage continued use of this method. In an
investigation of intrarun variability, correlation coefficients
of 0.89 or higher were achieved for triplicate runs of two
samples. Variables such as protein loading, pH range for
IPG strips, IEF conditions and albumin or globulin depletion
were tested and optimised [44]. An 8–16% gradient gel pro-
vides a better separation than linear gels and resolution
greatest with 50 mg of SF protein. Most of the proteins had a
pI between 4 and 7 and apparent molecular weight less than
70 kDa. One hundred and thirty-nine valid protein spots
were visualised, 18 of which differed five-fold and nine spots
differed more than 100-fold among themselves, which were
differentially expressed across individual OA patients. MS
was not used in this instance, but instead identities were
inferred from Expasy 2-D plasma maps (http://expasy.org/
ch2d/). The authors claim a sensitivity of 1–2 ng, increased
by SYPRO ruby fluorescent postrun gel stain. A further
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
896 D. S. Gibson and M. E. Rooney Proteomics Clin. Appl. 2007, 1, 889–899
study by the same group used two software packages and
performed trail analyses, focussing on the efficiency of
attributes such as spot detection in SF [62]. We have used the
2-DE technique to characterise the SF specific proteins which
distinguish juvenile arthritis patients with recurrent inflam-
mation of the knee joint [43]. Fragments of the T-cell receptor
and collagen X were identified in SFs of children with per-
sistent inflammatory episodes. Further studies using more
sensitive fluorescence difference in gel electrophoresis
(DIGE) have revealed interesting distinctions between the
local and systemic molecular signatures of juvenile arthritis
subgroups (Fig. 3, manuscripts in preparation). The most
predominant proteins can be easily distinguished in distinct
spot trains and it is clear that the majority of fibrinogen
remains exclusively in the blood (Figs. 3A and B). A number
of proteins with synovial ‘specific’ expression are highlighted
and quantified to demonstrate the ability to reliably differ-
entiate molecular fingerprints of local and systemic disease
across patient groups by this gel-based approach (Fig. 3A and
C).
Aside from gel electrophoresis, several other separation
methods have been used to process SF in the liquid phase
prior to MS. A number of small molecules including oligo-
saccharides from glycosaminoglycan digests, estrogens and
androgens, and bacteria-derived muramic acid have been
detected in SF pre-MS by liquid and GC separations [63–65].
A recent study adopted a two dimensional liquid chromato-
graphic approach (LC/LC) coupled with MS/MS) to generate
protein profiles from prefractionated SF [66]. Selected reac-
tion monitoring (previously known as MRM) acquires data
from specific product ions which correspond to mass/charge
selected precursor ions These product ions can be recorded
via two or more stages of MS in a temporal or spatial manner
so the relative abundance of a protein can be determined
across several different samples. Thirty SF proteins were
selected due to their raised levels in erosive RA than non-
erosive RA, including C reactive protein (detected at 49-fold
higher levels in erosive patients) and the metabolic enzyme
triosephosphate isomerase (TPI) [41]. Attention was focused
on the S100 family of calcium binding proteins (A4, A8, A9,
A11, A12 and P) and their ability to discriminate erosive
from nonerosive patients was tested on pooled sera. Only
S100A8, A9 and A12 were increased in erosive versus non-
erosive RA patients with fold difference ranges of 3.0–6.0-
fold, 9.4–14.1-fold and 4.4–11.1-fold, respectively [66].
Advances in biochip and affinity based proteomic tech-
nologies have been applied to SF in a drive towards high
throughput, real time devices with near clinical application.
Uchida et al. [67] used the ProteinChip platform to detect
biomarker candidates which can distinguish between RA
and OA. Surface enhanced laser desertion/ionisation MS
identified myeloid related protein 8 (MRP8) among these
candidates, in agreement with previously mentioned studies
of RA. Results from peptide fingerprint mapping and PSD
analysis were verified by enzyme immunoassay. The authors
propose that the ProteinChip platform could provide clini-
cally useful markers, though further study is required to
characterise temporal expression patterns as disease pro-
gresses. Surface plasmon resonance detection of antibody–
antigen interactions in biochip format has also been applied
to the study of SFautoantibodies [68]. This detection has real-
time measurement qualities, can be used in a nonredundant
manner and is not reliant on labelled antibodies. An inhibi-
tor affinity extraction method has been used to extract and
enrich individual MMPs from SF onto a sepharose cartridge
[69]. This process was automated on an SPE workstation and
the identity of each extracted MMP was confirmed by gelatin
zymography. What is really significant about this approach is
that the function of active molecules (i.e. the active enzyme
only in this case) can be probed and assayed in the diseased
joint. The authors claim that MMP extraction yields of ap-
proximately 98% could be achieved with as little as 13 s
sample contact time with the affinity matrix [69]. In theory if
the automated extraction techniques applied in this study
were coupled with modern MS identification, extremely
rapid sample turn around times could be achieved.
5.2 Serum/plasma analysis
A similar range of proteomic technologies have been used to
examine and validate SF findings in a parallel approach to
find serum/plasma based indicators of joint disease. Auto-
antibodies have been detected binding to chondrocyte anti-
genic proteins in sera separated by 2-D gel from arthritic
patients [70]. Ninteen protein spots were recognised only by
antibodies present within OA era. Of these, antitriose-
phosphate isomerase antibodies were detected in ,24% of
OA patient’s serum and SF samples, whereas ,6% of RA
and lupus patient samples were positive.
Hueber et al. used a custom autoantigen microarray to
detect B cell derived autoantibodies which target citrullinated
proteins and peptides in serum. RA patients could be strati-
fied by cluster analysis of autoantibody levels to citrulinated
or native proteins, into groups predictive of disease severity
[71]. Commercially available BioChips (Ciphergen) have also
been used recently to differentiate serum protein profiles
indicative of response to conventional therapeutics in juve-
nile idiopathic arthritis patients with severe systemic onset
disease [72].
The same principles of sample separation and analysis
can be used to focus on molecules other than proteins in
serum and SF. Phospholipids have been identified by
MALDI and characterised as indicators of disease severity in
the early stages of RA [73]. Furthermore, diminished disease
activity in patients who display a response to anti-TNFa
therapy is accompanied by corresponding increases in the
ratio of phosphatidylcholine/lysophosphatidylcholine in
plasma. The peptidome of SF has also been analysed by
MALDI after RP HPLC fractionation to enrich the low mo-
lecular weight protein [47]. Over 500 peptide signals have
been recorded in SF and over 5000 in plasma [74]. Once
cleaved into low molecular weight peptides, many proteins
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may have functions beyond our original perceptions. Peptide
profiles could be used to differentiate disease subgroups to
predict patients more likely to suffer severe disease [75].
5.3 Synovial cell and tissue proteomics
It is likely that markers of bone and cartilage destruction and
synovial specific cell migration would also be useful in the
clinical setting. Of course several specific subproteomes are
secreted from and are contained within the proximal tissue
and cells suspended in SF. The current state of proteomic
research on chondrocytes, fibroblasts and cells which have
migrated into the inflamed joint are therefore also briefly
described.
Hulkower et al. utilised radioactive isotope labelling (32P)
to study rabbit synovial chondrocyte response to interleukin-1
alpha treatment. Phosphoproteins formed by the incorpora-
tion of the 32P isotope for 30 min could be visualised by mak-
ing autoradiographs of cell extracts separated by 2-DE. Inter-
leukin-1 alpha produced marked changes in the pattern of
protein phosphorylation [76], which were similar to those
introduced by synovial cytokines. Activated chondrocytes have
been shown to produce proteins which participate in cartilage
degradation of joints [77]. A number of studies focus on the
proteomeof immune system cellswhich enter the joint via the
inflamed synovium [78–80]. Human peripheral monocytes,
sourced from SF, labelled overnight in vitro using 35S-
methionine metabolic labelling to quantify protein secretion.
Culture medium conditioned by labelled PMN cells was sepa-
rated by 2-DE and visualised by autoradiography. Thrombo-
spondin secretion was confirmed by immunoprecipitation
and the authors propose that abnormally high levels may
indirectly induce destructive changes within the SM [79].
Serum amyloid A derived fragments (98–104) detected in
rheumatic SFs by HPLC-MS are capable of stimulating inter-
feron gamma production by CD4 positive T-lymphocytes [80].
A number of proteomic studies have focused on fibro-
blast-like cells, also known as synovial lining cells or syno-
viocytes, as they also participate in the propagation of
arthritic disorders [81–85]. In the most recent study, Dasuri et
al. [83] investigated the synovial fibroblast proteome by 2-DE
MALDI-MS, identifying a number of potential autoantigens
and proteins previously implicated in RA disease pathology.
Other groups also used a gel-based separation and MS iden-
tification approach to investigate the mode of action of non-
steroidal anti-inflammatory drugs, and to detect serine pro-
tease secretion from synovial fibroblasts isolated from
arthritis patients [84].
These studies collectively demonstrate the power of
investigating the cells suspended in SF as they can make
specific additions to the SF proteome in joint health or dis-
ease. Synovial cell pellets should therefore be retained as a
valuable resource, which contribute additional levels of per-
ception concerning the complexity of the SF proteome and
how it may be used in a clinical situation for diagnostic or
prognostic measurements. Furthermore, they may present
putative targets to direct more specific antiinflammatory and
antidegradative therapeutics, which could resolve disease
persistence and prevent joint damage.
Proteome analysis of SM tissue could lead to further
understanding of the causes of joint pathology. As the initia-
tors of synovium inflammation and hyperplasia remain elu-
sive, it is important to gain samples from the earliest stages
of arthritic disease. Early gel based experiments were able to
differentiate the histomorphology of cryostat sections as the
characteristic of either exudative or proliferative synovitis
and probe for autoantigens in RA [86, 87]. Modern gene array
and multi-Western blot platforms have been used to simul-
taneously characterise transcript and protein levels in RA
compared to OA in a patient’s synovial tissue [88]. The
authors report that changes in transcript levels did not
always translate into changes in the corresponding protein
levels. Protein localisation and expression levels confirmed
by immunohistochemistry demonstrated that stat 1, involved
in interferon signal transduction, was overexpressed in peri-
vascular macrophages and CD3 positive T-lymphocytes in
RA patients [88]. More recently, Tilleman et al. [89] demon-
strated the ability to segregate spondyloarthropathy patients
from RA and OA patient groups by hierarchical cluster anal-
ysis of differentially expression patterns derived from a 2-DE-
MS investigation of inflamed synovium. Considered togeth-
er, synovial tissue analysed in combination with fluids could
reveal biomarkers secreted by various types of SM cells as
disease progresses from early clinically unapparent disease
to established chronic inflammation. The study of synovium
by proteomic platforms should be considered as a key to our
understanding of the stages of cellular pathology involved in
the development of joint diseases.
6 Clinical application of synovial
proteomics
The application of global proteomic rationales to the study of
SF, plasma and synovial cells and tissue provides the oppor-
tunity to tackle a wide variety of clinical challenges encoun-
tered with a multifaceted disease such as arthritis. These
challenges are clearly defined in a recent review of proteom-
ics to study autoimmunity by Hueber and Robinson [90] and
include the ability to identify patients more likely to develop
severe disease or screening therapeutic response in a given
individual. Profiling disease state-specific changes in the SF
proteome represents a powerful approach to provide perso-
nalised treatment tailored to individual patients.
The concept of individualised medicine through the char-
acterisation of changes in proteome response has been pro-
posed for both plasma and SF [47, 50, 91]. Long-term patient
‘proteome records’ showing gradual disease associated
changes over time, may allow tracking and refinement of
therapeutic responses in a given individual [91]. Several stud-
ies demonstrate the potential of proteomics to monitor the
changes in serial SFsamples, collected during clinical trials of
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novel biological drugs [59, 92]. What is more, proteomic anal-
ysis offers a suitable alternative to conventional molecular
measures of disease status and progression, particularly
where limited sample volume may restrict the number of
singular assays which can be processed per patient.
Existing biomarkers which relate to the extent of inflam-
mation do not act as sentinels of joint damage, which can
occur in patients with clinically unapparent disease, nor do
they portray the efficacy of treatment. Classic measures of
acute phase response, erthyrocyte sedimentation rate (ESR)
and C reactive protein correlate well with concurrent inflam-
matory activity and correlate with clinical improvement but
are poor predictors of future severity [41, 92]. Large-scale
proteomic analysis of SF is therefore of particular importance
not only in monitoring therapeutic responses, but also holds
a great potential to diagnose arthritic disorders [50].
7 Conclusions
Many technologies have been used in the field of SF prote-
omics, including MS, 2-DE, ELISA, and protein microarray.
The data derived by such techniques are thus inevitably
composed of heterogeneous measurements that require
integration to allow comparison. Data normalisation and
scaling techniques will be critical in building predictive
models of arthritic disease. The clinical challenges in arthri-
tis are to develop robust biomarkers for predictors of out-
come and disease progression. To this end, clinicians and
scientists need to work in tandem. Clinicians must ensure
that patient’s disease and subtype are rigorously categorised
according to internationally recognised criteria. Detailed
clinical assessments are undertaken and that samples are
obtained and stored according to protocols. Scientists must
ensure that their methodologies are undertaken in such a
way that their techniques are sensitive, findings reproducible
and pertinent to the clinical questions asked.
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